Epigallocatechin-3-gallate (EGCG) attenuates non-alcoholic fatty liver disease via modulating the interaction between gut microbiota and bile acids

The spectrum of non-alcoholic fatty liver disease (NAFLD) ranges from simple hepatic steatosis commonly associated with obesity, to non-alcoholic steatohepatitis, which can progress to fibrosis, cirrhosis and hepatocellular carcinoma. Recent reports have indicated the crucial role of gut microbiota...

Descripción completa

Detalles Bibliográficos
Autores principales: Naito, Yuji, Ushiroda, Chihiro, Mizushima, Katsura, Inoue, Ryo, Yasukawa, Zenta, Abe, Aya, Takagi, Tomohisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: the Society for Free Radical Research Japan 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417793/
https://www.ncbi.nlm.nih.gov/pubmed/32801462
http://dx.doi.org/10.3164/jcbn.20-39

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417793/
https://www.ncbi.nlm.nih.gov/pubmed/32801462
http://dx.doi.org/10.3164/jcbn.20-39

Ejemplares similares